Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (2242)	12/7/2000 1:43:19 AM
From: Doc Bones	Read Replies (1) \| Respond to of 52153

Well, my guess is that the stock will be soft after the offering.I expect a move down to about 25$. Well, I'd have to call that speculative, Spekulatius. <g> Recent secondaries in biotech have been strong, notably the IMNX offering, which wound up totaling $3.2 Billion! The announcement of the $30 / share deal was done in the morning, and the stock moved quickly over $32. It was an interesting, very heavy volume day. siliconinvestor.com The action in NBIX tracked the Nasdaq and biotech indexes, except that the fall at the end of day was much more severe. That fall was accompanied by unusually heavy volume, which I think is sometimes a sign of shorting. The awful market (yesterday aside) makes the short position much more viable, and biotech has never lacked for their attention. I'll add more on those little short people I see following me around soon. And remember, just because your paranoid doesn't mean they're not out to get you! Doc